JP2007314574A - Slightly digestible agent - Google Patents

Slightly digestible agent Download PDF

Info

Publication number
JP2007314574A
JP2007314574A JP2007213477A JP2007213477A JP2007314574A JP 2007314574 A JP2007314574 A JP 2007314574A JP 2007213477 A JP2007213477 A JP 2007213477A JP 2007213477 A JP2007213477 A JP 2007213477A JP 2007314574 A JP2007314574 A JP 2007314574A
Authority
JP
Japan
Prior art keywords
sericin
agent
hours
test
constipation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007213477A
Other languages
Japanese (ja)
Other versions
JP4695629B2 (en
Inventor
Masahiro Sasaki
真宏 佐々木
Hideyuki Yamada
英幸 山田
Masakazu Nomura
正和 野村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seiren Co Ltd
Original Assignee
Seiren Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seiren Co Ltd filed Critical Seiren Co Ltd
Priority to JP2007213477A priority Critical patent/JP4695629B2/en
Publication of JP2007314574A publication Critical patent/JP2007314574A/en
Application granted granted Critical
Publication of JP4695629B2 publication Critical patent/JP4695629B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a new adiposity-inhibiting/constipation-releasing agent. <P>SOLUTION: This slightly digestible agent contains sericin or it's hydrolyzed product as an active ingredient. The slightly digestible agent, wherein the sericin is natural sericin extracted from cocoon or silk. <P>COPYRIGHT: (C)2008,JPO&INPIT

Description

本発明は難消化剤に関し、特に脂肪蓄積抑制/便秘解消剤に関する。   The present invention relates to an indigestible agent, and more particularly to a fat accumulation inhibitor / constipation relieving agent.

人の消化酵素で消化されない成分である食物繊維は、食生活の欧米化に伴い摂取量が年々減少している。しかしその一方で、その低カロリー性、血糖値の改善、便秘解消などの効果が見直されてきている。さらに近年の美容、健康への関心の高まりにより、実に様々な食物繊維を含んだ食品・飲料が提案、市販されている。   Dietary fiber, an ingredient that is not digested by human digestive enzymes, is decreasing year by year with the westernization of diet. However, on the other hand, its effects such as low calorieity, improvement of blood sugar level and elimination of constipation have been reviewed. Furthermore, with the recent increase in interest in beauty and health, foods and beverages containing various dietary fibers have been proposed and marketed.

例えば特許文献1には、低分子化したコンニャクマンナンからなる食物繊維を含む飲料が提案されている。
その他にも特許文献2にはキノコ類から得られたもの、特許文献3には低分子ペクチン、特許文献4にはアルギン酸類など、実に多数の食物繊維が提案されている。
For example, Patent Document 1 proposes a beverage containing dietary fiber made of konjac mannan having a low molecular weight.
In addition, Patent Document 2 proposes a large number of dietary fibers such as those obtained from mushrooms, Patent Document 3 with low molecular weight pectin, and Patent Document 4 with alginic acids.

現在飲食品用として使用されている多くは水溶性の食物繊維である。この種の食物繊維はゲル化しやすい性質を持ち、粘性が高いため、飲食物に添加するには低粘度化してやらねばならず、製造法が複雑になってしまう。また、摂取した場合には腹部に多量のガスが発生するなどの問題がある。
特開平7−313120号公報 特開平5−199849号公報 特開平6−169724号公報 特開平2−303468号公報
Many currently used for food and drink are water-soluble dietary fibers. This type of dietary fiber has a property of being easily gelled and has a high viscosity, so that it must be reduced in viscosity to be added to food and drink, and the manufacturing method becomes complicated. Moreover, when ingested, there is a problem that a large amount of gas is generated in the abdomen.
JP 7-313120 A Japanese Patent Laid-Open No. 5-199849 JP-A-6-169724 JP-A-2-303468

本発明は脂肪蓄積抑制(ダイエット)及び便秘解消作用を有する新規な難消化剤を提供することを目的とするものである。   An object of the present invention is to provide a novel indigestible agent having an action of suppressing fat accumulation (diet) and relieving constipation.

本発明はセリシン及び/又はその加水分解物を有効成分とする難消化剤である。 The present invention is an indigestible agent containing sericin and / or a hydrolyzate thereof as an active ingredient.

本発明で用いるセリシンとしては通常、繭又は生糸由来のセリシンが好ましく用いられる。非加水分解物としてのセリシンは、繭又は生糸から一般的に行われる抽出方法で得ることができる。例えば以下のようにして純度90%以上の高精製度単一タンパク質の状態で抽出できる。   As sericin used in the present invention, usually sericin derived from silkworms or raw silk is preferably used. Sericin as a non-hydrolyzate can be obtained by an extraction method generally performed from straw or raw silk. For example, it can be extracted in the state of a highly purified single protein having a purity of 90% or more as follows.

即ち、繭又は生糸に含有されるセリシンを水によって抽出し、例えば次の(1)、(2)のいずれかの方法で回収する。
(1)メタノール、エタノール、ジオキサン等の水溶性有機溶媒を混合してセリシンを析出させた後、これを濾別乾燥して、セリシン粉体として得る。
(2)特開平4−202435号公報に提案されているように、限外濾過膜もしくは逆浸透膜に付した後、乾燥することによりセリシン粉体を得る。
That is, sericin contained in cocoons or raw silk is extracted with water and recovered by, for example, any one of the following methods (1) and (2).
(1) A water-soluble organic solvent such as methanol, ethanol, dioxane or the like is mixed to precipitate sericin, which is then filtered and dried to obtain sericin powder.
(2) As proposed in JP-A-4-202435, a sericin powder is obtained by applying an ultrafiltration membrane or a reverse osmosis membrane, followed by drying.

またセリシンの加水分解物は、繭又は生糸から一般的に行われる抽出方法で得ることができる。
即ち、繭又は生糸に含有されるセリシンを、電気分解した水や、酸、アルカリもしくは酵素などによって部分加水分解して抽出してから、例えば同様に上記(1)、(2)のいずれかの方法で回収する。
Moreover, the hydrolyzate of sericin can be obtained by an extraction method generally performed from straw or raw silk.
That is, sericin contained in silkworms or raw silk is extracted by partial hydrolysis with electrolyzed water, acid, alkali or enzyme, and then, for example, either of the above (1) and (2) Collect by method.

繭はその良質なタンパク質が注目され、粉砕するなどして栄養源として食品に添加することが提案されているが、その繭タンパク質の一つであるセリシンが体内の消化酵素に対して消化性が低く、ダイエットや便秘解消に効果的であるということは全く知られていない。   The high quality protein of salmon has attracted attention, and it has been proposed to add it to food as a nutrient source by crushing it. However, sericin, one of the salmon proteins, is digestible to digestive enzymes in the body. It is not known at all to be low and effective in reducing diet and constipation.

難消化性であるセリシンは、腸内の活動を活発化させ、便の大腸通過時間を短縮させる働きがあり、有害・有毒物質を速やかに体外に排出させる。また余分な糖や脂質などを吸収しにくくするなど、食物繊維のような作用を示す。
このような直接的な効果だけでなく、吸収した水分により排便がスムーズになるなどの効果も有している。
Sericin, which is indigestible, activates activities in the intestines and shortens the transit time of the stool to the large intestine, and quickly releases harmful and toxic substances out of the body. It also acts like dietary fiber, making it difficult to absorb excess sugar and lipids.
In addition to such a direct effect, there are also effects such as smooth defecation due to absorbed moisture.

このセリシンは天然物由来であるため人体への安全性が高く、一般食品、一般飲料、さらには健康食品、特定保険用食品などの特別用途食品、その他経口摂取する適宜のもの(これらを本発明では飲食品と総称する)に添加して用いることができ、日常の食生活において無理なく摂取可能である。さらに水に可溶であるため、飲食品に添加しやすく様々な形状とすることができる。   Since this sericin is derived from a natural product, it is highly safe for the human body, and is suitable for general foods, general drinks, foods for special uses such as health foods, foods for specified insurance, etc. Can be added and used without difficulty in daily eating habits. Furthermore, since it is soluble in water, it can be easily added to foods and drinks and can have various shapes.

難消化剤としての好ましい形状の例としては、粉末状、溶液状、ゲル状、スティック状、顆粒状、カプセル状、錠剤がある。
摂取量も無毒性故特に制限はなく、通常1日の摂取量は1〜30g程度である。
Examples of preferable shapes as the indigestible agent include powder, solution, gel, stick, granule, capsule, and tablet.
The intake is not particularly limited because it is non-toxic, and the daily intake is usually about 1 to 30 g.

次に実施例により本発明を例証する。
〔製造例1〕 セリシン粉体の製造
繭1kgを水50L(リットル)中で95℃にて2時間処理し、セリシンを抽出した。得られた抽出液を平均孔径0.2μmのフィルターで濾過し、凝集物を除去した後、濾液を逆浸透膜により脱塩し、濃度0.2%の無色透明のセリシン水溶液を得た。この水溶液をエバポレーターを用いてセリシン濃度約2%にまで濃縮した後、凍結乾燥を行って、純度95%以上、平均分子量100,000のセリシン粉体(以下セリシンH)100gを得た。
The following examples illustrate the invention.
[Production Example 1] Production of sericin powder 1 kg of koji was treated in 50 L (liter) of water at 95 ° C for 2 hours to extract sericin. The obtained extract was filtered through a filter having an average pore size of 0.2 μm to remove aggregates, and the filtrate was desalted with a reverse osmosis membrane to obtain a colorless and transparent sericin aqueous solution having a concentration of 0.2%. This aqueous solution was concentrated to a sericin concentration of about 2% using an evaporator and then freeze-dried to obtain 100 g of sericin powder (hereinafter referred to as sericin H) having a purity of 95% or more and an average molecular weight of 100,000.

〔製造例2〕 セリシン加水分解物粉体の製造
繭1kgを0.2%炭酸ナトリウム水(pH11〜12)50L中で95℃にて2時間処理し、セリシン加水分解物を抽出した。得られた抽出液を平均孔径0.2μmのフィルターで濾過し、凝集物を除去した後、濾液を逆浸透膜により脱塩し、濃度0.2%の無色透明のセリシン加水分解物抽出液を得た。この抽出液をエバポレーターを用いてセリシン濃度約2%にまで濃縮した後、凍結乾燥を行って、純度90%以上、平均分子量20,000のセリシン加水分解物粉体(以下セリシンL)100gを得た。
[Production Example 2] Production of sericin hydrolyzate powder 1 kg of koji was treated in 50 L of 0.2% aqueous sodium carbonate (pH 11-12) at 95 ° C for 2 hours to extract sericin hydrolyzate. The obtained extract was filtered with a filter having an average pore size of 0.2 μm to remove aggregates, and then the filtrate was desalted with a reverse osmosis membrane to give a colorless transparent sericin hydrolyzate extract with a concentration of 0.2%. Obtained. This extract was concentrated to a sericin concentration of about 2% using an evaporator and then lyophilized to obtain 100 g of a sericin hydrolyzate powder (hereinafter referred to as sericin L) having a purity of 90% or more and an average molecular weight of 20,000. It was.

〔試験例1〕 消化性試験
消化試験の試料としてセリシンLまたはカゼインを用い、各試料濃度が0.5%(pH2.0)溶液になるように塩酸を用いて調製し、蒸留水で100mlに合わせた。胃の消化酵素であるペプシン(シグマ社)5mg試料溶液に加え、37℃で24時間インキュベートし、適時にサンプリングを行った。インキュベート終了後、試料溶液100mlを0.1%(pH8.5)になるよう炭酸水素ナトリウムを用いて調製した。その後、十二指腸の消化酵素であるパンクレアチン(シグマ社)を2mg加え37℃で24時間インキュベートを行った。
[Test Example 1] Digestibility test Using sericin L or casein as a sample for the digestion test, each sample concentration was adjusted to 0.5% (pH 2.0) solution using hydrochloric acid and made up to 100 ml with distilled water. Combined. The sample was added to a 5 mg sample solution of pepsin (Sigma), which is a digestive enzyme of the stomach, incubated at 37 ° C. for 24 hours, and sampled at an appropriate time. After completion of the incubation, 100 ml of the sample solution was prepared using sodium hydrogen carbonate so as to be 0.1% (pH 8.5). Thereafter, 2 mg of pancreatin (Sigma), a digestive enzyme of the duodenum, was added and incubated at 37 ° C. for 24 hours.

ペプチドの濃度測定はTNBS(2,4,6−トリニトロベンゼンスルホン酸)法を用いて行った。サンプリングは全て0.5mlを採取し、30%TCA(トリクロロ酢酸)を0.1ml加え、遠心分離後、上清100μlに7%炭酸水素ナトリウムを3ml、0.1%TNBSを2ml加えて、37℃で2時間加温し、420nmの吸光度を測定した。
結果を図1、図2に示した。本試験では体内での消化酵素であるペプシンやパンクレアチンに対する影響を試験管内で確認した。TNBS法はタンパク質のアミノ末端と反応し、消化酵素で分解され易いほど、ペプチドが多く存在するためTNBS試薬との反応性が高まる。つまり値が高いほど消化酵素に対して分解されやすいことになる。カゼインに比べてセリシンはペプシン、パンクレアチンのいずれの消化酵素でも難消化性であることが確認された。
The peptide concentration was measured using the TNBS (2,4,6-trinitrobenzenesulfonic acid) method. For sampling, 0.5 ml was collected, 0.1 ml of 30% TCA (trichloroacetic acid) was added, and after centrifugation, 3 ml of 7% sodium bicarbonate and 2 ml of 0.1% TNBS were added to 100 μl of the supernatant. The mixture was heated at 0 ° C. for 2 hours, and the absorbance at 420 nm was measured.
The results are shown in FIGS. In this test, the effects on pepsin and pancreatin, which are digestive enzymes in the body, were confirmed in vitro. The TNBS method reacts with the amino terminus of a protein, and the more easily it is degraded by a digestive enzyme, the more the peptide is present, the more reactive with the TNBS reagent. In other words, the higher the value, the easier it is to decompose with digestive enzymes. Compared with casein, sericin was confirmed to be indigestible with both pepsin and pancreatin digestive enzymes.

〔試験例2〕 消化管輸送能試験
実験動物として、5週令の雄ICR系マウスを用いた。1群当たり10匹とし室温を24±1℃に保ち、12時間ごとの明暗交替(8:00〜20:00は明、20:00〜翌8:00は暗)の環境下で飼育を行った。予備飼育として1週間、市販の固形試料(MF、オリエンタル酵母(株))を与えた。試験日前日、終夜絶食させた後、1時間摂食させ摂食量がほぼ一定の動物を選別し、1群8匹として実験に用いた。消化管輸送能のマーカーとしてBTB(投与量:0.3%溶液を1匹当たり0.35ml)を経口投与し、同時にセリシンL(投与量:2g/体重kg)またはコントロール(カゼイン、投与量:2g/体重kg)を経口投与した。投与後25時間まで経時的に糞を採取した。この間、6時間及び23時間後に各1時間ずつ摂食させた。糞のBTB***量を測定した後、糞を24時間減圧乾燥し糞乾燥重量を測定した。なお有意差の判定にはStudentのt−検定を用いた。
[Test Example 2] Gastrointestinal transport ability test As a test animal, a 5-week-old male ICR mouse was used. 10 animals per group, keeping the room temperature at 24 ± 1 ° C., and rearing in an environment of light / dark alternation every 12 hours (8: 00 to 20: 00 is light, 20: 00 to the next 8:00 is dark) It was. A commercially available solid sample (MF, Oriental Yeast Co., Ltd.) was given for 1 week as a preliminary breeding. The animals were fasted overnight on the day before the test day and then fed for 1 hour to select animals with a substantially constant food intake, and 8 animals per group were used in the experiment. BTB (dose: 0.35 ml of 0.3% solution per mouse) was orally administered as a marker of gastrointestinal transport ability, and sericin L (dose: 2 g / kg body weight) or control (casein, dose: 2 g / kg body weight) was administered orally. Feces were collected over time until 25 hours after administration. During this time, the animals were fed for 1 hour each after 6 hours and 23 hours. After measuring the fecal BTB excretion, the feces were dried under reduced pressure for 24 hours, and the fecal dry weight was measured. Student's t-test was used to determine the significant difference.

その結果、セリシン群は糞重量がコントロール群に比べて有意に増加していた(図3)。糞の性状はコントルール群に比べてやや大きく、柔らかめであったが、水様便、粘液便などの下痢症状は見られなかった。
またコントロール群で摂食後、2〜4時間で糞中にBTBが見出され始め、6時間までにBTB総投与量の33.5%、8時間までに53.5%、25時間までに88.3%が***された。一方セリシン群では摂食後4〜8時間のBTB***率がコントルール群に比べて有意に高く、セリシンは消化管輸送速度を高める効果を確認した(図4)。
As a result, the sericin group significantly increased the fecal weight compared to the control group (FIG. 3). Feces were slightly larger and softer than the control rule group, but no diarrhea such as watery or mucous stool was observed.
In addition, BTB began to be found in feces 2 to 4 hours after feeding in the control group, 33.5% of the total dose of BTB by 6 hours, 53.5% by 8 hours, and 88 by 25 hours 3% was excreted. On the other hand, in the sericin group, the BTB excretion rate 4 to 8 hours after feeding was significantly higher than that in the control rule group, and sericin confirmed the effect of increasing the gastrointestinal transport rate (FIG. 4).

〔試験例3〕 便秘改善効果試験
実験動物として3週令の雄Sprague−Dawley系ラット(日本LSC(株))を用い、1群13匹とした。1匹ずつ金属ケージに入れ、室温を24±1℃に保ち、12時間ごとの明暗交替の環境下で飼育を行った。予備飼育として2週間、市販の固形試料(MF、オリエンタル酵母(株))を与えた後、セリシン群、コントロール群の2群に分け、実験食(表1)で7日間飼育を行った。なお1群は14匹とし、食事時間は全て14:00〜17:00に限定した。実験食開始から7日目の17:00に、各群を平均体重が等しくなるように2つのグループに分け、それぞれアトロピン塩酸塩(0.5mg/体重kg)または生理食塩水を腹腔内注射により投与した。注射後6時間(17:00〜23:00)の糞を採取し、減圧乾燥後、乾燥重量とした。なお有意差の判定にはDuncanの多重比較検定を用いた。
ヒトの便秘の多くは機能性便秘である。これは腸管平滑筋が副交換神経からアセチルコリンの遊離が減少することで、消化管運動や肛門機能を抑制した結果生じる便秘である。実験に用いたアトロピンはナス科のベラドンナから得られるアルカロイドに由来し、副交感神経遮断薬として用いられる為、アセチルコリン及びアセチルコリン様薬物の可逆的拮抗物質として機能性便秘を誘導する。
表2の結果より、セリシンはアトロピン投与によって低下した消化管機能の改善が認められたことから、セリシンの便秘改善効果を確認した。
[Test Example 3] Constipation-improving effect test Three-week-old male Sprague-Dawley rats (Japan LSC Co., Ltd.) were used as experimental animals, and each group consisted of 13 animals. Each animal was placed in a metal cage, kept at a room temperature of 24 ± 1 ° C., and bred in an environment of light / dark alternation every 12 hours. As a preliminary breeding, a commercially available solid sample (MF, Oriental Yeast Co., Ltd.) was given for 2 weeks, and then divided into two groups, a sericin group and a control group, and fed on an experimental diet (Table 1) for 7 days. One group consisted of 14 animals, and all meal times were limited to 14: 00-17: 00. At 17:00 on the seventh day from the start of the experimental diet, each group was divided into two groups so that the average body weights were equal, and atropine hydrochloride (0.5 mg / kg body weight) or physiological saline was injected intraperitoneally, respectively. Administered. Feces 6 hours after the injection (17: 00 to 23:00) were collected, dried under reduced pressure, and taken as the dry weight. Duncan's multiple comparison test was used to determine the significant difference.
Most human constipation is functional constipation. This is constipation resulting from the suppression of gastrointestinal motility and anal function by reducing the release of acetylcholine from the intestinal smooth muscle of the intestinal smooth muscle. The atropine used in the experiment is derived from an alkaloid obtained from the belladonna of the solanaceae family and is used as a parasympathetic nerve blocker, and therefore induces functional constipation as a reversible antagonist of acetylcholine and acetylcholine-like drugs.
From the results in Table 2, since sericin was found to improve the gastrointestinal function decreased by atropine administration, the effect of sericin on improving constipation was confirmed.

Figure 2007314574
Figure 2007314574

Figure 2007314574
Figure 2007314574

〔試験例4〕 脂肪蓄積抑制効果試験
実験動物として5週令の雄ICR系マウス(日本LSC(株))を用いた。1群12匹とし、表3に示す飼料及び水を自由摂取させ、室温を24±1℃に保ち、12時間ごとの明暗交替の環境下で8週間飼育を行った。試験終了後マウスを屠殺、解剖し、体重および腎付着脂肪重量を測定した。脂肪は体重当たりの腎付着脂肪重量割合を算出し、これを腎付着脂肪率とした。さらに血液から常法により血清を得て、トリグリセライド測定キット(トリグリセライド G−テストワコー 和光純薬工業(株))を用いて血清中のトリグリセライド濃度を測定した。なお有意差の判定にはDuncanの多重比較検定を用いた。
結果を表4に示した。各群の食事摂取量には有意差が見られなかったが、コントロール群に比べてセリシン群はセリシンの添加量に伴って、体重の抑制が確認された。さらにセリシン群では腎付着脂肪率も抑制し、血清中のトリグリセライド濃度も低下したことから、セリシンは脂肪の蓄積を抑制していることが確認された。
[Test Example 4] Fat accumulation inhibitory effect test As a laboratory animal, a 5-week-old male ICR mouse (Japan LSC Co., Ltd.) was used. Each group consisted of 12 animals, and was allowed to freely ingest the feed and water shown in Table 3, kept at room temperature of 24 ± 1 ° C., and reared for 8 weeks in an environment of alternating light and darkness every 12 hours. After the test was completed, the mice were sacrificed and dissected, and the body weight and kidney attached fat weight were measured. For fat, the weight ratio of kidney-attached fat per body weight was calculated, and this was defined as the kidney-attached fat ratio. Further, serum was obtained from blood by a conventional method, and the triglyceride concentration in the serum was measured using a triglyceride measurement kit (Triglyceride G-Test Wako, Wako Pure Chemical Industries, Ltd.). Duncan's multiple comparison test was used to determine the significant difference.
The results are shown in Table 4. Although no significant difference was observed in the dietary intake of each group, suppression of body weight was confirmed in the sericin group with the amount of sericin added compared to the control group. Furthermore, in the sericin group, the rate of fat adhering to the kidneys was also reduced, and the triglyceride concentration in the serum was also reduced, confirming that sericin inhibited fat accumulation.

Figure 2007314574
Figure 2007314574

Figure 2007314574
Figure 2007314574

セリシンは難消化性であり、胃や腸の働きを活性化させ、胃や腸内で余分な水分やコレステロール、有害物質、中性脂肪などを吸収しにくくし、脂肪蓄積抑制(ダイエット)や便秘解消効果に大いに効果がある。又セリシンは天然物由来のタンパク質としての特性を持ち、生体内では高い安全性を有するので、たとえ大量に摂取したとしても無害である。従って、日常の食生活において無理なく摂取可能であり、その効果はいっそう顕著なものとなりうる。   Sericin is indigestible, activates the function of the stomach and intestines, makes it difficult to absorb excess water, cholesterol, toxic substances, neutral fat, etc. in the stomach and intestines, suppresses fat accumulation (diet) and constipation There is a great effect on the cancellation effect. In addition, sericin has properties as a protein derived from natural products and has high safety in vivo, so it is harmless even if ingested in large quantities. Therefore, it can be taken without difficulty in daily eating habits, and the effect can be even more remarkable.

更に、本発明の有効成分であるセリシンは繭又は生糸の溶媒抽出物から、容易にしかも単一のタンパク質としては高い純度で抽出できるため、安価に得られ、しかも水溶液の色が無色透明であるので、消色する必要が無く、複雑な処理工程を必要としないという大きな利点がある。   Furthermore, since sericin, which is an active ingredient of the present invention, can be easily extracted from a cocoon or raw silk solvent extract with high purity as a single protein, it can be obtained at low cost, and the color of the aqueous solution is colorless and transparent. Therefore, there is a great advantage that there is no need to decolorize and no complicated processing steps are required.

消化試験(対ペプシン)の結果を示すグラフ。The graph which shows the result of a digestion test (vs pepsin). 消化試験(対パンクレアチン)の結果を示すグラフ。The graph which shows the result of a digestion test (vs. pancreatin). 消化管輸送能を糞量で測定した結果を示すグラフ。The graph which shows the result of having measured the digestive tract transport ability with the amount of feces. 消化管輸送能をBTB***率で測定した結果を示すグラフ。The graph which shows the result of having measured the gastrointestinal transport ability with the BTB excretion rate.

Claims (3)

セリシン又は/及びその加水分解物を有効成分とすることを特徴とする難消化剤。   An indigestible agent comprising sericin or / and a hydrolyzate thereof as an active ingredient. セリシンが繭又は生糸から抽出した天然セリシンである請求項1記載の難消化剤。   The indigestible agent according to claim 1, wherein the sericin is natural sericin extracted from silkworms or raw silk. 脂肪蓄積抑制/便秘解消剤である請求項1又は2記載の難消化剤。   The indigestible agent according to claim 1 or 2, which is a fat accumulation inhibitor / constipation relieving agent.
JP2007213477A 1999-03-04 2007-08-20 Indigestible Expired - Lifetime JP4695629B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007213477A JP4695629B2 (en) 1999-03-04 2007-08-20 Indigestible

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP5699399 1999-03-04
JP1999056993 1999-03-04
JP2007213477A JP4695629B2 (en) 1999-03-04 2007-08-20 Indigestible

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000063327A Division JP4027559B2 (en) 1999-03-04 2000-03-03 Mineral absorption promoter

Publications (2)

Publication Number Publication Date
JP2007314574A true JP2007314574A (en) 2007-12-06
JP4695629B2 JP4695629B2 (en) 2011-06-08

Family

ID=38848742

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007213477A Expired - Lifetime JP4695629B2 (en) 1999-03-04 2007-08-20 Indigestible

Country Status (1)

Country Link
JP (1) JP4695629B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009041121A1 (en) * 2007-09-28 2011-01-20 株式会社Kazkiインターナショナル Cosmetic auxiliary patch and makeup method using the patch

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02177864A (en) * 1988-12-29 1990-07-10 Terumo Corp Food containing hydrolyzate of silk protein and preparation thereof
JPH10140154A (en) * 1996-11-08 1998-05-26 Seiren Co Ltd Antioxidant
JPH10265403A (en) * 1997-03-24 1998-10-06 Seiren Co Ltd Tyrosinase activity inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02177864A (en) * 1988-12-29 1990-07-10 Terumo Corp Food containing hydrolyzate of silk protein and preparation thereof
JPH10140154A (en) * 1996-11-08 1998-05-26 Seiren Co Ltd Antioxidant
JPH10265403A (en) * 1997-03-24 1998-10-06 Seiren Co Ltd Tyrosinase activity inhibitor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009041121A1 (en) * 2007-09-28 2011-01-20 株式会社Kazkiインターナショナル Cosmetic auxiliary patch and makeup method using the patch
JP4672799B2 (en) * 2007-09-28 2011-04-20 株式会社Kazkiインターナショナル Cosmetic auxiliary patch and makeup method using the patch

Also Published As

Publication number Publication date
JP4695629B2 (en) 2011-06-08

Similar Documents

Publication Publication Date Title
JP2805194B2 (en) Peptide for increasing blood triglyceride concentration and blood triglyceride concentration increase inhibitor containing the peptide as an active ingredient
JP2001178429A (en) Functional antidiabetic drink
JP3749978B2 (en) Bone formation enhancing composition exhibiting anti-osteoporosis effect
JP2004097021A (en) Wakame protein-containing composition, and wakame protein-containing food
JP4695629B2 (en) Indigestible
US20070275875A1 (en) Method for preventing colon cancer
JP4027559B2 (en) Mineral absorption promoter
RU2713935C1 (en) Peptides of marine origin and fish nucleotides, compositions and use thereof for reducing blood glucose
JP2002275087A (en) Antidiabetic medicine and food for preventing diabetes
MXPA96005979A (en) Novedous use of gluten peptides as absorption stimulants of minerals and as preventive agents of hyperlipidemia and hypercolesterole
CN102105160A (en) Compositions and methods for increasing serum antioxidant concentrations
JPH07215851A (en) Antiallergic agent and its production
JP2004010569A (en) Arginine-containing peptide having cholecystokinin secretion promoting activity and food containing the same
JP2579593B2 (en) Health food containing calcium-containing composition excellent in absorbability, drug containing the composition
US4323496A (en) Innoxious interferon-inducing substance, inducing agent and process for producing same
JP4412757B2 (en) Colon cancer preventive
JP3605528B2 (en) Weight gain inhibitor
JPH0984552A (en) Calcium-containing composition excellent in absorbing property
EP2117342B1 (en) Feed composition for salmonids and uses thereof
JPS6144822A (en) Health promoting and keeping agent containing chondroitin sulfate
JPH08157385A (en) Bowl movement improver, agent for enhancing prolifration of gut mucosa and perpectal nutrition promoting agent
JPH10114674A (en) Promoter of mineral absorption and preventive for hyperlipemia and hypercholesterolemia
JPH05320058A (en) Blood lipid-lowering agent containing hyaluronic acid
KR20040022392A (en) Laver protein-containing composition and foods
WO2021159031A1 (en) Digestive aid for plant-based proteins

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101124

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110201

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110225

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140304

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4695629

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term